PMID- 31805690
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 11
IP  - 12
DP  - 2019 Dec 1
TI  - A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention.
LID - 10.3390/cancers11121909 [doi]
LID - 1909
AB  - Dendritic cells (DCs) are potent antigen-presenting cells that play a critical 
      role in activating cellular and humoral immune responses. DC-based tumor vaccines 
      targeting tumor-associated antigens (TAAs) have been extensively tested and 
      demonstrated to be safe and potent in inducing anti-TAA immune responses in 
      cancer patients. Sipuleucel-T (Provenge), a cancer vaccine of autologous DCs 
      loaded with TAA, was approved by the United States Food and Drug Administration 
      (FDA) for the treatment of castration-resistant prostate cancer. Sipuleucel-T 
      prolongs patient survival, but has little or no effect on clinical disease 
      progression or biomarker kinetics. Due to the overall limited clinical efficacy 
      of tumor vaccines, there is a need to enhance their potency. PD-L1 is a key 
      immune checkpoint molecule and is frequently overexpressed on tumor cells to 
      evade antitumor immune destruction. Repeated administrations of PD-L1 or PD-1 
      antibodies have induced sustained tumor regression in a fraction of cancer 
      patients. In this study, we tested whether vaccinations with DCs, loaded with a 
      PD-L1 immunogen (PDL1-Vax), are able to induce anti-PD-L1 immune responses. We 
      found that DCs loaded with PDL1-Vax induced anti-PD-L1 antibody and T cell 
      responses in immunized mice and that PD-L1-specific CTLs had cytolytic activities 
      against PD-L1(+) tumor cells. We demonstrated that vaccination with PDL1-Vax DCs 
      potently inhibited the growth of PD-L1(+) tumor cells. In summary, this study 
      demonstrates for the first time the principle and feasibility of DC vaccination 
      (PDL1-Vax) to actively induce anti-PD-L1 antibody and T cell responses capable of 
      inhibiting PD-L1(+) tumor growth. This novel anti-PD-L1 vaccination strategy 
      could be used for cancer treatment and prevention.
FAU - Chen, Jie
AU  - Chen J
AD  - Pomona Biotechnology Corp., 605 E Huntington Drive, Monrovia, CA 91016, USA.
FAU - Liu, Hui
AU  - Liu H
AD  - Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer 
      Center, Keck School of Medicine, University of Southern California, 1450 Biggy 
      St, Los Angeles, CA 90033, USA.
FAU - Jehng, Tiffany
AU  - Jehng T
AD  - Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer 
      Center, Keck School of Medicine, University of Southern California, 1450 Biggy 
      St, Los Angeles, CA 90033, USA.
FAU - Li, Yanqing
AU  - Li Y
AD  - Pomona Biotechnology Corp., 605 E Huntington Drive, Monrovia, CA 91016, USA.
FAU - Chen, Zhoushi
AU  - Chen Z
AUID- ORCID: 0000-0001-5370-3082
AD  - Pomona Biotechnology Corp., 605 E Huntington Drive, Monrovia, CA 91016, USA.
FAU - Lee, Kuan-Der
AU  - Lee KD
AD  - Department of Hematology and Oncology, Taipei Medical University Hospital and 
      Department of Medicine, Taipei Medical University, Taipei 110, Taiwan.
FAU - Shen, Hsieh-Tsung
AU  - Shen HT
AD  - Department of Hematology and Oncology, Taipei Medical University Hospital and 
      Department of Medicine, Taipei Medical University, Taipei 110, Taiwan.
AD  - Jiyan Biomedical Corp., Taipei 110, Taiwan.
FAU - Jones, Lindsey
AU  - Jones L
AD  - Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer 
      Center, Keck School of Medicine, University of Southern California, 1450 Biggy 
      St, Los Angeles, CA 90033, USA.
FAU - Huang, Xue F
AU  - Huang XF
AD  - Pomona Biotechnology Corp., 605 E Huntington Drive, Monrovia, CA 91016, USA.
FAU - Chen, Si-Yi
AU  - Chen SY
AD  - Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer 
      Center, Keck School of Medicine, University of Southern California, 1450 Biggy 
      St, Los Angeles, CA 90033, USA.
LA  - eng
GR  - internal funds/Pomona Biotechnology Corp./
PT  - Journal Article
DEP - 20191201
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC6966557
OTO - NOTNLM
OT  - PD-L1
OT  - dendritic cells
OT  - immune checkpoint
OT  - immunotherapy
OT  - tumor vaccine
COIS- J.C., Y.L., Z.C., and X.F.H. are employees of Pomona Biotechnology Corp.
EDAT- 2019/12/07 06:00
MHDA- 2019/12/07 06:01
PMCR- 2019/12/01
CRDT- 2019/12/07 06:00
PHST- 2019/09/20 00:00 [received]
PHST- 2019/11/22 00:00 [accepted]
PHST- 2019/12/07 06:00 [entrez]
PHST- 2019/12/07 06:00 [pubmed]
PHST- 2019/12/07 06:01 [medline]
PHST- 2019/12/01 00:00 [pmc-release]
AID - cancers11121909 [pii]
AID - cancers-11-01909 [pii]
AID - 10.3390/cancers11121909 [doi]
PST - epublish
SO  - Cancers (Basel). 2019 Dec 1;11(12):1909. doi: 10.3390/cancers11121909.